Physician profile
Kathleen Steiger
NPI 1346674132
$4,065.83
in general payments reported to CMS, 2019-2025
16 companies · $1,950 in 2025
The $1,950 reported for 2025 was more than what 95% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.38 · 2023: $1,076 · 2024: $1,028 · 2025: $1,950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,053.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,205.70 | 2023-2025 | |
| Axsome Therapeutics, INC. | $573.10 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $428.77 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $325.83 | 2023-2025 | Lybalvi, Vivitrol, Aristada |
| Teva Pharmaceuticals USA, INC. | $317.53 | 2023-2024 | Austedo Xr, Uzedy |
| Novo Nordisk INC | $240.55 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Braeburn INC. | $219.07 | 2025 | Brixadi |
| Corium, LLC | $194.17 | 2023-2025 | Azstarys |
| Lundbeck LLC | $159.59 | 2023-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $155.86 | 2023-2024 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $87.44 | 2023-2025 | Trintellix |
| Lilly USA, LLC | $52.43 | 2021-2025 | Jardiance, Zepbound |
| Vanda Pharmaceuticals INC. | $39.50 | 2025 | Fanapt |
| Vertex Pharmaceuticals Incorporated | $28.59 | 2025 | |
| Indivior INC. | $20.31 | 2025 | Sublocade |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $17.39 | 2024 | Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Steiger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.